Clinicopathologic characteristics and oncologic outcomes in adenosarcoma of gynecologic sites

Li, Jessie Y.; Mutlu, Levent; Tymon‐Rosario, Joan; Khadraoui, Wafa; Nagarkatti, Nupur; Hui, Pei; Buza, Natália; Lu, Lingeng; Schwartz, Peter E.; Menderes, Gulden

doi:10.1016/j.gore.2021.100913

Cited by 3 publications

(2 citation statements)

References 32 publications

(56 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Because ER/PR expression is lower in tumors with sarcomatous overgrowth, the application of hormonal therapy should be limited. Although some studies have suggested that hormone therapy should be considered if ER/PR is positive, there is still a lack of clinical and research-based evidence for hormone therapy in treating adenosarcoma [ 38 , 39 ].…”

Section: Discussionmentioning

confidence: 99%

Mullerian adenosarcoma of the uterus with MASO: a case report of cervical adenosarcoma in a young female that never had sexual behavior

Chen,

Huang,

Wang

et al. 2024

BMC Women's Health

View full text Add to dashboard Cite

Background Cervical mullerian adenosarcoma is a rare uterine sarcoma, especially in young women. Its pathological features are low-grade malignant tumors with bidirectional differentiation, and the degree of malignancy is similar to that of low-grade endometrial stromal sarcoma. This paper reports the case of a young asexual patient who has been closely followed up after tumor resection and has not had any recurrences. Case presentation A 20-year-old, young asexual woman was diagnosed with cervical mullerian adenosarcoma with sarcomatous overgrowth (MASO). Cervical tumor resection was performed after admission, and the resection margin was negative. After the operation, she refused to undergo secondary surgery due to fertility requirements and did not receive adjuvant treatment. The patient was closely followed up after the operation and has not yet relapsed. Conclusion A young woman with cervical MASO did not receive adjuvant treatment after cervical tumor resection. For women with fertility requirements, close follow-ups should be conducted after the operation to guard against tumor recurrence and radical tumor resection should be performed as early as possible after the patient no longer requires their fertility.

show abstract

Section: Discussionmentioning

confidence: 99%

Mullerian adenosarcoma of the uterus with MASO: a case report of cervical adenosarcoma in a young female that never had sexual behavior

Chen,

Huang,

Wang

et al. 2024

BMC Women's Health

View full text Add to dashboard Cite

show abstract

“…The age of onset of UA ranges from 10 to 94 years (median age, above 50 years) [ 7 ] and is more common in postmenopausal women. Overall, UA has a better prognosis than other uterine sarcomas and carcinosarcomas [ 8 , 9 ]. However, Heveder et al [ 10 – 12 ] suggested a 50% reduction in survival in UA patients with adverse prognostic factors.…”

Section: Discussionmentioning

confidence: 99%

Next-Generation Sequencing Analysis of 3 Uterine Adenosarcomas with Heterogeneously Differentiated Genomic Mutations

Li,

Meng,

Luo

et al. 2023

International Journal of Analytical Chemistry

View full text Add to dashboard Cite

Uterine adenosarcoma (UA) is an uncommon mixed tumor containing a benign to at most mildly atypical epithelial component and a sarcoma-like stroma, usually a low-grade, stromal component, with rare heterogeneous elements. Currently, tumor etiology is largely unknown. To better understand the gene mutations in UA, next-generation sequencing (NGS) technology analysis was performed. This study showed that two low-grade UAs with heterologous components had ATRX gene frameshift mutation, and one patient had a MED12 missense mutation. Copy number amplification genes were mainly observed on chromosome 12q13–15. In this study, PIK3/AKT/PTEN pathway mutations were found to be common in adenosarcoma. In addition, a rare BCORL1-PRR14L fusion mutation was also identified. These findings provide a basis for future research into these molecular changes in tumorigenesis and targeted therapy.

show abstract

Endometriale und weitere seltene uterine Sarkome

et al. 2022

View full text Add to dashboard Cite

Clinicopathologic characteristics and oncologic outcomes in adenosarcoma of gynecologic sites

Cited by 3 publications

References 32 publications

Mullerian adenosarcoma of the uterus with MASO: a case report of cervical adenosarcoma in a young female that never had sexual behavior

Mullerian adenosarcoma of the uterus with MASO: a case report of cervical adenosarcoma in a young female that never had sexual behavior

Next-Generation Sequencing Analysis of 3 Uterine Adenosarcomas with Heterogeneously Differentiated Genomic Mutations

Endometriale und weitere seltene uterine Sarkome

Contact Info

Product

Resources

About